|
N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID
|
DB07952 |
|
|
N-[1H-INDOL-3-YL-ACETYL]VALINE ACID
|
DB07953 |
|
|
3-isobutyl-1-methyl-7H-xanthine
|
DB07954 |
|
|
(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE
|
DB07955 |
|
|
[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER
|
DB07956 |
|
|
METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE
|
DB07957 |
|
|
(2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)ACETIC ACID
|
DB07958 |
|
|
3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE
|
DB07959 |
|
|
Zibotentan
|
DB06629 |
|
|
Axitinib
|
DB06626 |
[Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.] |
|
Vipadenant
|
DB06625 |
|
|
Taranabant
|
DB06624 |
|
|
Flupirtine
|
DB06623 |
[Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.] |
|
7-beta-Hydroxyepiandrosterone
|
DB06622 |
|
|
Aplindore
|
DB06620 |
|
|
Indoleacetic acid
|
DB07950 |
|
|
N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
|
DB07920 |
|
|
2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
|
DB07921 |
|
|
N-oxo-2-(phenylsulfonylamino)ethanamide
|
DB07922 |
|
|
octyl alpha-L-altropyranoside
|
DB07923 |
|
